VRDN
Viridian Therapeutics, Inc.
Biotechnology · Healthcare · United States
24.67
close · 2026-10-30
value
47
cheaper than peers47
quality
56
stronger fundamentals56
ranked against
Biotechnology (commercial)
value
quality
162 peerswide variation
Value inputs
| measure | company | vs peers |
| cash flow yield, 3 years ago | -3.4% | 67 |
| cash flow yield, 2 years ago | -6.6% | 55 |
| cash flow yield, 1 year ago | -8.3% | 55 |
| earnings yield, 1 year ago | -12.4% | 54 |
| cash flow yield, latest year | -9.9% | 50 |
| earnings yield, 3 years ago | -16.4% | 49 |
| earnings yield, latest year | -13.5% | 47 |
| earnings yield, 2 years ago | -21.5% | 46 |
| price to book | 4.95× | 36 |
| price to sales | 39.29× | 26 |
10 of 12 measures available
Quality inputs
| measure | company | vs peers |
| revenue growth | 278.7% | 87 |
| return on equity | -65.7% | 38 |
| debt to equity | 37.0% | 35 |
3 of 4 measures available
Facts
| market cap | $3B |
| free cash flow | -$275.5M |
| employees | 252 |
| first trade | 2014-06-18 |
| next earnings | 2026-11-04 |
| fundamentals updated | 2026-08-10 |
Annual history
| measure | 2025 | 2024 | 2023 | 2022 | 2021 |
| diluted eps | -3.32 | -3.07 | -5.31 | -4.05 | not reported |
| free cash flow | -$276.9M | -$232.8M | -$185.1M | -$94.6M | not reported |
| net income | -$342.6M | -$269.9M | -$237.7M | -$129.9M | not reported |
| revenue | $70.8M | $302,000 | $314,000 | $1.8M | not reported |
| unusual items | not reported | not reported | not reported | not reported | $0 |